Bupropion-SR in treatment of social phobia

Depress Anxiety. 2000;12(2):111-3. doi: 10.1002/1520-6394(2000)12:2<111::AID-DA9>3.0.CO;2-3.


A 12-week, open label flexible dosing study was conducted to evaluate the efficacy of bupropion-SR in the treatment of generalized social phobia. The primary outcome measures include the Clinical Global Impression of Improvement (CGI-I) and the Brief Social Phobia Rating Scale (BSPS). A total of 18 subjects were enrolled. Five of the ten subjects who completed all 12 weeks were considered as responders. Response to treatment was defined as a CGI-I score of 1 or 2, ("much improved" or "very much improved," respectively) and a > 50% decrease in BSPS score. The final doses for the completers ranged between 200 and 400 mg/day (mean 366 +/- 68 mg/day). The medication was generally well tolerated. Findings from this open-label trial suggest that bupropion-SR may be useful in treating generalized social phobia.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Antidepressive Agents, Second-Generation / administration & dosage
  • Antidepressive Agents, Second-Generation / therapeutic use*
  • Bupropion / administration & dosage
  • Bupropion / therapeutic use*
  • Delayed-Action Preparations
  • Female
  • Humans
  • Male
  • Phobic Disorders / diagnosis
  • Phobic Disorders / drug therapy*
  • Treatment Outcome


  • Antidepressive Agents, Second-Generation
  • Delayed-Action Preparations
  • Bupropion